NCT00860275View on ClinicalTrials.gov

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Alzheimer Disease
Interventions
DRUG

BMS-708163

Capsule, Oral, 50 mg, once, Day 1

DRUG

BMS-708163 + Ketoconazole

(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day

DRUG

Ketoconazole

Tablet, Oral, 400 mg, daily, 16 days

DRUG

Fluconazole

Tablet, Oral, 1 day 400 mg then 3 days 200 mg

DRUG

BMS-708163 + Fluconazole

(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days

Trial Locations (1)

78744

Ppd Development, Lp, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00860275 - Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole | Biotech Hunter | Biotech Hunter